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Abstract 
Background. Most of the existing risk scores for identifying people with reduced estimated 
glomerular filtration rate (eGFR) involve laboratory-based factors, which are not convenient 
and cost-effective to use in large population-based screening program. We aimed at using 
non-invasive variables to identify subjects with reduced eGFR in a Chinese working 
population. 
Methods. Two study populations were recruited in 2012 and 2015, respectively. The 2012 
study population (n=14,374) was randomly separated as the training dataset (n=9,621) or the 
internal testing dataset (n=4,753) at a ratio of 2:1, and the 2015 study population (n=4,371) 
was used as the external testing dataset. Stepwise logistic regression analysis with age, 
gender, hypertension and body mass index (BMI) status were first performed in the training 
dataset and then validated in both internal and external testing dataset. A nomogram was 
further developed based on the final model.  
Results. Results showed that older females with higher BMI status were more likely to have 
reduced eGFR. The model had excellent discrimination (AUC: 0.887 [95%CI: 0.865, 0.909] 
in the internal validation and 0.880 [95%CI: 0.829, 0.931] in the external validation) and 
calibration (Hosmer-Lemeshow test, P=0.798 and 0.397 for internal and external dataset, 
respectively). The probability of having reduced eGFR increased gradually from <0.1% at a 
total score of 0 to 26% at a total score of 58 shown in the nomogram.  
Conclusion. Non-invasive variables could help identify individuals at high risk of reduced 
eGFR for further kidney function testing or intervention, aiding in decision-making and 
resource allocation in large population screening. 
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In this study conducted in selected ethnic working class Uighur Chinese population, the 
authors show that advanced age, female sex and higher body mass index are associated with 
the likelihood of having reduced eGFR 
Keywords: 
Innovative model, nomogram, non-invasive variables, reduced eGFR, working population 
Introduction 
Chronic kidney disease (CKD) is a major public health issue that has been linked to ageing, 
hypertension, diabetes and unhealthy lifestyle.
1
 As a key factor for the diagnosis, 
classification and staging of CKD, glomerular filtration rate (GFR) measures the flow rate of 
filtered fluid through the kidney.
2
 It is considered the best indicator of the overall kidney 
function and an important clinical tool for health and disease in the daily care.
2
 However, 
GFR is not readily assessable directly. Several different formula, as a result, have been 
developed using clinical available parameters.
3, 4
 Nowadays, the estimated GFR (eGFR) is 
widely used in the clinical decision-making process for renal dysfunction and renal dialysis.
2
  
 
Reduced eGFR (<60 mL/min/1.73 m
2
) is categorized as stage 3 – 5 CKD according to the 
Kidney Disease – Improving Global Outcomes (KDIGO) guidelines, indicating a substantial 
reduction in kidney function.
2
 Reduced eGFR is also associated with increased risk of 
cardiovascular disease (CVD) and all-cause mortality,
5
 it is therefore urgent and important to 
identify individuals with reduced eGFR at an early stage and execute appropriate 
management, in order to prevent or delay the onset of the adverse outcomes. However, a cost-
effectiveness study showed that screening reduced eGFR in the general population is not as 
cost-effective as targeting subgroups, such as diabetes patients.
6
 Nevertheless, there is a 
substantial proportion of patients with diabetes are undiagnosed, and this figure is up to 
60.7% in China.
7
 Thus, it is not feasible to screen reduced eGFR among the high-risk groups, 
in considering the high rate of undiagnosed diabetes.  
Several risk scores were developed to identify individuals with high risk of reduced eGFR.
8-17
 
However, most of these studies involved laboratory tests, which may be cumbersome to be 
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used in population-based screening program. Thus, in this study, we aimed at estimating the 
prevalence of reduced eGFR and establishing a model using non-invasive variables in a 
working population, in order to identify subjects with reduced eGFR for further kidney 
function testing or intervention for preventing adverse outcomes. 
Methods 
Settings and study population  
This cross-sectional study was conducted from January to December 2012 in the People’s 
Hospital of Xinjiang Uygur Autonomous Region, located in the northwest of the People’s 
Republic of China. Another population was recruited from January to March 2015 at the 
same hospital. The two populations were working individuals coming to the health 
examination center at the hospital for body check arranged by their companies/institutes. 
Inclusion criteria included adults older than 18 years and having given consent to this study. 
All the eligible participants during the study recruitment periods were invited. Individuals 
were excluded from subsequent statistical analysis if 1). without age information or were less 
than 18 years old; 2). without body mass index (BMI) information; 3). without blood pressure 
(BP) measurement and 4). without serum creatinine test. The study design was shown in 
Figure 1. All the participants were provided with a written consent. The demographic and 
clinical data were subsequently collected anonymously. This study was approved by the 
hospital’s ethics committee according to the 1975 Declaration of Helsinki.  
 
 
Measurements 
Demographic data including age and gender were self-reported by participants. BMI was 
calculated from participant’s measured body weight and height, with overweight and obesity 
defined as BMI value between 23−24.9 kg/m2 and  ≥ 25 kg/m2, respectively, based on the 
WHO Asian cut-off value.
18
 BP was measured after at least 5 minutes of rest. Hypertension 
was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or on anti-
hypertensive medication at the time of health examination. Blood samples were collected 
after overnight fasting to assess the levels of serum creatinine, fasting blood glucose and lipid 
profile (total cholesterol, triglycerides, high density lipoprotein [HDL]-cholesterol and 
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calculated low density lipoprotein [LDL]-cholesterol). Serum total cholesterol, triglycerides 
and HDL-cholesterol were measured using enzymatic techniques (Abbott Japan Co., Ltd., 
Tokyo, Japan). 
Serum creatinine was assessed using kinetic colorimetric methods, which has been 
standardized against the isotope dilution mass spectrometry (IDMS) (Abbott Japan Co., Ltd., 
Tokyo, Japan). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
creatinine equation was used to calculate eGFR based on age, gender and serum creatinine.
3
 
Reduced eGFR was defined as eGFR<60 mL/min/1.73 m
2
 and served as the primary outcome 
of our study.   
 
Statistical analysis 
The 2012 study population was randomly separated into two parts, with 2/3 of the total 
participants as the training dataset and the remaining participants as the internal testing 
dataset. The 2015 study population was served as the external testing dataset. Descriptive 
characteristics were summarized as means ± standard deviation (SD) or numbers (percentage), 
as appropriate. To compare the differences between participants with reduced eGFR and 
those without in 2012 study population, and between training dataset and internal or external 
testing datasets, independent two-sample t-test was used for continuous data, and Chi-square 
test was used for categorical variables.  
 
In order to identify the significant factors associated with reduced eGFR, stepwise logistic 
regression model was applied to the training dataset first and then validated on both internal 
and external testing datasets. To facilitate risk score calculation and clinical use, we 
categorized continuous variables as binary or categorical variables with arbitrary cut-off 
points. Age groups (≤40, 41−50, 51−60, 61−70, and ≥71 years), gender, hypertension and 
BMI status (<23 for normal, 23−24.9 for overweight and ≥25 kg/m2 for obese) were coded 
and entered into the model. All the variables with a p value less than 0.1 were kept in the 
final model. The variables in the final model were used to establish a nomogram. First, each 
variable was assigned a score by multiplying the respective β-coefficients by 10 and rounded 
to the nearest integer. Second, variable axes were constructed for each variable with the 
length in accordance with the variable score. Last, an axe of the total score (sum of the scores 
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for each variable) and an axe of the corresponding estimated probability of having reduced 
eGFR was drawn. The area under the receiver-operating characteristic curve (AUC) was used 
to evaluate the model discrimination. An AUC of 0.7 – 0.8 is defined as acceptable 
discrimination; between 0.8 – 0.9 is defined as excellent discrimination and over 0.9 is 
defined as outstanding discrimination.
19
 The Hosmer-Lemeshow test was used to assess the 
model calibration when a p value of test greater than 0.05 indicating no statistically 
significant difference between the predicted outcome in the model and the observed 
outcome.
19
 Youden’s index was used to determine the optimal cut-off score for predicting 
reduced eGFR.
20
 We further added laboratory assessments of fasting blood glucose, 
triglyceride and LDL-cholesterol into the model and compared the performance with the 
model incorporating non-invasive variables only, in order to see whether there is any 
incremental AUC. 
 
Statistical analyses were performed using STATA 13 (Stata Corp, College Station, TX, USA). 
All the statistical tests were two-sided and statistical significance was set at p<0.05. 
 
Results 
A total of 20,182 individuals were invited and 17,537 subjects (86.9%) were finally recruited 
with consent form in 2012. We excluded those aged less than 18 years (n = 28); without BP 
or BMI measurements (n = 271) and those without serum creatinine measurement (n = 2,864). 
The 2012 study population therefore included 14,374 participants with 8,154 males and 6,221 
females. The mean (SD) age was 45.3 (14.3) years. No significant difference in age or gender 
was found between participants included and excluded from the study. Similarly, 6,016 
individuals were invited in 2015 and 5,304 subjects (88.2%) were recruited with consent 
form. A total of 4,371 subjects were finally included as the external testing dataset (Figure 1).  
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In the 2012 study population, the prevalence of reduced eGFR was 2.05% (95%CI: 1.81, 
2.28%). Compared to people with normal eGFR levels, those with reduced eGFR were older 
(68.6 ± 11.8 vs 44.8 ± 13.9 years, p < 0.001) and more likely to be overweight or obese 
(77.5% vs 64.6%, p < 0.001) (Table 1). Furthermore, subjects with reduced eGFR had higher 
systolic BP, diastolic BP, hypertension prevalence, total cholesterol, triglycerides and fasting 
blood glucose levels, compared to people with normal eGFR. 
 
Around 2/3 (n = 9,621) of the total 2012 participants were randomly assigned into the 
training dataset, and the remaining 4,753 were entered into the internal testing dataset (Table 
2). There were no statistically significant differences found in any item measured between the 
training dataset and the internal testing dataset. Compared to the training dataset, participants 
from the external testing dataset were younger and most of them were males (63.7%). 
Furthermore, they were more likely to be obese, but less likely to have hypertension. In terms 
of the kidney function, the 2015 study population had lower serum creatinine and higher 
eGFR levels compared to the training dataset. Only 1.01% of the 2015 study population was 
diagnosed as reduced eGFR. 
 
Stepwise logistic regression was first applied in the training dataset. Age groups, BMI status 
and gender were kept in the final model (Table 3). This model had an AUC of 0.887 (95%CI: 
0.865, 0.909) and the Hosmer-Lemeshow test had a p value of 0.955 (Table 4). The optimal 
cut-off point was score 36, with an acceptable sensitivity of 0.820 and specificity of 0.863. 
The logistic regression model with age groups, BMI status and gender were further applied in 
the internal testing dataset and the model had an AUC of 0.894 (95%CI: 0.861, 0.926) with a 
p value of 0.798 in the Hosmer-Lemeshow test. Similarly, the model in the external testing 
dataset had an AUC of 0.880 (95%CI: 0.829, 0.931) and a p value of 0.397 in the Hosmer-
Lemeshow test. A nomogram incorporating age groups, BMI status and gender was further 
developed to estimate the probability of having reduced eGFR in the working population 
(Figure 2). 
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After including fasting blood glucose, triglyceride and LDL-cholesterol into the stepwise 
logistic analysis, obesity was no longer a significant factor and was ruled out from the model, 
while triglyceride was kept in the final model (data not shown). However, there were no 
significant incremental AUC of the new model compared to the model only incorporating 
non-invasive variables. 
 
Discussion 
The present cross-sectional study was conducted in a relatively large scale of working 
population, having 2.05% of subjects screened with reduced eGFR according to the CKD-EPI 
formula. From the model demonstrating excellent discrimination and calibration during both 
internal and external validations, female gender, older age and larger BMI were associated 
with increased risk of reduced eGFR. A nomogram incorporating these three items was 
further developed to estimate the probability of having reduced eGFR in the working 
population, which could be used as a strategy of risk stratification before any evaluation of 
laboratory test.  
 
In the United States, the National Health and Nutrition Examination Surveys showed that the 
prevalence of reduced eGFR was around 5.6% in the 1988-1994 survey and increased to 
around 8.1% in the 1999-2004 survey.
21
 Nevertheless, the prevalence of reduced eGFR in 
China is relatively low.
22-25
 Two national-wide studies reported that the prevalence of 
reduced eGFR was 1.7% among subjects aged 18 years or older,
24
 and 2.53% in another 
study focusing on adults aged between 34 – 74 years old.25 Our study further showed that the 
prevalence of reduced eGFR was around 2.05% in the working population. Although it was 
relatively low compared to the United States, the situation might be aggravated in the future 
due to the aging population and increasing epidemic of diabetes and hypertension in China. 
Furthermore, substantial disparities of reduced eGFR prevalence in geographical regions 
were demonstrated in these studies. There were several possible explanations for such 
differential prevalence of reduced eGFR. First, as a developing country, the distribution of 
economic development, lifestyle factors, dietary habits, health literacy and access to medical 
care varied greatly, especially between rural and urban areas.
26
 Second, there are several 
standardized formulas to estimate GFR.
3, 4, 27
 One of the national-wide studies used the 
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Modification of Diet in Renal Disease (MDRD) equation to estimate GFR,
25
 another study 
used the adopted Chinese version of the MDRD equation,
24
 while our study used the CKD-
EPI formula, which has been demonstrated superior accuracy than the MDRD formula.
28
 
Thus, it is plausible that the prevalence of reduced eGFR in our study was different from the 
two previous population studies in China.
24, 25
 
 
Many available risk scores have been established to either identify the prevalent
8-10
 or 
incident cases of reduced eGFR
11-17
 in clinic settings or population-based studies. However, 
most of these studies required laboratory-based measures or information of previous disease 
diagnosis, e.g. diabetes. Only one study evaluated the risk model using age and sex, resulting 
a c-statistic of 0.776.
13
 Better model performance in our study might be attributable to the 
inclusion of BMI status and a more detailed category of age. We demonstrated that ageing is 
a key risk factor for reduced eGFR, which might be due to the reduction in renal blood flow 
and renal mass.
29, 30
 Hypertension was ruled out from the final model because of statistical 
non-significance. It might be a result of the close association between ageing and 
hypertension in our study population, in which hypertension was explained by ageing effect 
in the model.  
 
Screening reduced eGFR among asymptomatic people is undergoing debate over the cost and 
the effective therapy or intervention. On one hand, there is insufficient evidence from 
randomized controlled trial
31
 to suggest that screening for reduced eGFR can prevent or delay 
the adverse outcomes of end-stage renal disease or CVD at an early stage.
5
 Nevertheless, we 
should bear in mind that insufficient evidence for screening does not imply that screening for 
reduced eGFR is ineffective. On the other hand, it is not cost-effective to screen for reduced 
eGFR in the general population. In a large scale general health survey conducted in Norway, 
results showed that 20.6 people needed to be screened in order to identify one case with 
reduced eGFR.
32
 It has been proven not to be a cost-effective strategy in the general 
population with an estimated cost per quality adjusted life years gained of 104, 900 Canadian 
dollars (equal to 83,000 US dollars), compared to a figure of 22,600 Canadian dollars (equal 
to 17,870 US dollars) in diabetes patients,
6
 which provided us with a feasible and cost-
effective strategy. However, in China, around 60.7% of the diabetes patients are 
undiagnosed,
7
 indicating a substantial gap of screening prevalent reduced eGFR in this high-
risk group in developing countries.   
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There are several potential implications from this study. First, the score-based system allows 
not only the occupational health physicians but also the layman to understand the risk of 
having reduced eGFR, which may aid further decision-making process. Second, using non-
invasive variables may broaden the application in the general population, especially in rural 
areas. Third, the simple and easily defined nomogram may increase the awareness of kidney 
disease in the general population, as it is estimated that the overall awareness rate of CKD 
was only 10.4% in a representative sample of the general population in China.
33
 Last, we did 
not find any incremental AUC after including laboratory assessment. Our results suggested 
that in clinical practice, a two-stage process might be more efficient and cost-effective. The 
first step is to identify those with high risk of reduced eGFR using non-invasive variables, 
such as age, sex, BMI, blood pressure and other relevant information and followed by a 
second step of laboratory measures for serum creatinine, which would be applied only to 
people with high risk to further confirm the findings. Suitable interventions, such as losing 
weight, reducing blood pressure or changing diet habits, should be further applied to people 
with reduced eGFR in order to prevent adverse outcomes of severe kidney disease, CVD and 
mortality.
5
 However, the cost-effectiveness of the two-stage strategy needs further 
investigation. 
 
Strengths and limitations 
There are several strengths of this study. Firstly, we included a large study population. 
Secondly, all the assessments were conducted in the same assessment center, which minimize 
the measurement errors and confounding effects of various tests. Thirdly, the model 
developed in our study was further validated both internally and externally, revealing 
excellent discriminations and calibration. Lastly, we developed a nomogram, which would be 
used as a risk-stratification tool to identify those at high risk of reduced eGFR in the working 
population and general population at large.  
 
The limitations of this study deserved discussion. First, the cross-sectional nature of these 
data precludes us from exploring the casual relationship between these non-invasive variables 
and reduced eGFR. However, several previous cohort studies have already well-documented 
that older age, female and obesity were related to reduced eGFR,
34, 35
 which supported the 
findings in our study. Second, we have arbitrarily converted continuous variables into 
categorical data to facilitate risk score calculation and nomogram establishment, although 
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most risk factors were continuous data. Third, the generalizability of our study to other 
populations needs further investigation. Fourth, we cannot rule out the influence of other 
unmeasured confounders. For example, cigarette smoking
34
 and sedentary behaviors
36
 have 
been linked to increased risk of reduced eGFR. However, in this study, we were unable to 
address this association. Last, urine albumin to creatinine ratio is also an important aspect of 
CKD, linking with end-stage renal disease and CVD. Nevertheless, due to the lack of 
information on urine albumin and creatinine measures, we were unable to predict CKD as the 
study outcome. 
 
Conclusion 
In conclusion, age, gender and BMI status were associated with detection of reduced eGFR in 
a working population. The validated model incorporating these three variables would be 
integrated as a simple tool to identify those with high risk of reduced eGFR and allocate 
appropriate resources to them accordingly. Although people with reduced eGFR without 
progressing receive little treatment or intervention by urologists, it should be recognized that 
most of these people die from CVD, rather than progressing to end-stage renal disease,
37
 
which signifies the importance of identifying these people from the general population. 
However, even though the prevalence of reduced eGFR is relatively low in China when 
compared to other countries, the absolute burden is substantial in considering the large 
population size. The nomogram developed in our study thus would be used to efficiently 
allocate resources to screen and intervene high risk individuals. 
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Figure 1. Design and participants flow of this study, 2012 and 2015. Abbreviation: BP, blood 
pressure; BMI, body mass index. 
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Figure 2. Nomogram for identifying reduced eGFR from asymptomatic working population 
using non-invasive variables. Abbreviation: BMI, body mass index; eGFR, estimated 
glomerular filtration rate. Overweight was defined as BMI between 23−24.9 kg/m2 and 
obesity was defined as BMI≥25 kg/m2 in this Asian population. To use the nomogram, first, 
draw a straight upward line to the “Points” axis and determine the points contributed by 
gender. Repeat the same process for BMI status and age group. Second, get the total points 
by adding the points from gender, BMI status and age group. Last, find the point in the “Total 
Points” axis and draw a straight downward line to the “Estimated probability of having 
reduced eGFR” and read the estimated probability.  For an obese (5 points) female subject (5 
points) aged 77 years (48 points), the total points were 58, and the corresponding probability 
of having reduced eGFR was 0.26. 
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Table 1. Demographic and Clinical Characteristics of the 2012 Study Population According 
to the Reduced eGFR Diagnosis, Urumqi, China, 2012 
    
Overall 
participants  
(n = 14374) 
Normal eGFR            
(n = 14080) 
Reduced 
eGFR         
(n = 294) 
P 
value
 a
 
Age, years 45.3 (14.3) 44.8 (13.9) 68.6 (11.8) <0.001 
Sex 
   
0.493 
 
Male 8153 (56.7%) 7992 (56.8%) 161 (54.8%) 
 
 
Female 6221 (43.3) 6088 (43.2%) 133 (45.2%) 
 
BMI
b
 24.5 (3.5) 24.5 (3.5) 25.4 (3.4) <0.001 
BMI status
c
 
   
<0.001 
 
Normal weight 5043 (35.1%) 4977 (35.3%) 66 (22.4%)  
 
Overweight 3303 (23.0%) 3242 (23.0%) 61 (20.7%) 
 
 
Obesity 6028 (41.9%) 5861 (41.6%) 167 (56.8%) 
 
Systolic BP, mm Hg 122.8 (19.3) 122.5 (19.1) 134.9 (21.5) <0.001 
Diastolic BP, mm Hg 78.2 (12.8) 78.1 (12.8) 79.8 (13.1) 0.030 
Hypertension 3640 (25.3%) 3501 (24.9%) 139 (47.3%) <0.001 
Serum creatinine, μmol/L 77.2 (19.7) 76.3 (14.0) 123.5 (85.7) <0.001 
eGFR, mL/minute/1.73 m
2
 95.5 (16.4) 96.5 (15.2) 51.0 (10.0) <0.001 
Fasting blood glucose, mmol/L 4.8 (1.5) 4.8 (1.4) 5.5 (2.3) <0.001 
Total cholesterol, mmol/L 4.5 (1.3) 4.5 (1.3) 4.8 (1.3) <0.001 
Triglycerides, mmol/L 1.8 (1.5) 1.8 (1.5) 2.2 (1.9) 0.001 
HDL-cholesterol, mmol/L 1.0 (0.7) 1.0 (0.7) 0.9 (0.8) 0.350 
LDL-cholesterol, mmol/L 1.8 (1.4) 1.8 (1.4) 1.8 (1.5) 0.637 
 
Abbreviation: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular 
filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; SD, Standard 
deviation. 
a P values refer to comparisons between subjects with and without reduced eGFR, using 
Student’s t test or Pearson’s χ2 test. 
b
 BMI = weight (kg)/height (m)
2
. 
c
 Overweight was defined as BMI between 23−24.9 kg/m2 and obesity was defined as 
BMI≥25 kg/m2 in this Asian population. 
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Table 2. Comparison of Demographic and Clinical Characteristics between the Training Dataset and the Internal or External Testing Dataset, 
Respectively, Urumqi, China, 2012 and 2015  
    2012 study populationa 
P 
value
b
 
  2015 study population 
P 
value
c
 Characteristic 
Training dataset             
(n = 9621) 
Internal testing 
dataset   (n = 4753) 
  
External testing dataset 
(n = 4371) 
Age, years 45.4 (14.3) 45.2 (14.3) 0.448 
 
41.8 (11.7) <0.001 
Sex 
     
<0.001 
 
Male 5456 (56.7%) 2697 (56.7%) 
  
2786 (63.7%) 
 
 
Female 4165 (43.3%) 2056 (43.3%) 
  
1585 (36.3%) 
 
BMI
d
 24.5 (3.5) 24.5 (3.6) 0.612 
 
24.7 (4.4) 0.016 
BMI status
e
 
      
 
Normal weight 3347 (34.8%) 1696 (35.7%) 0.358 
 
1601 (36.6%) <0.001 
 
Overweight 2222 (23.1%) 1081 (22.7%) 
  
728 (16.7%) 
 
 
Obesity 4052 (42.1%) 1081 (41.6%) 
  
2042 (46.7%) 
 
Systolic BP, mm Hg 122.8 (19.3) 122.6 (19.2) 0.415 
 
125.6 (22.5) <0.001 
Diastolic BP, mm Hg 78.2 (12.8) 78.0 (12.9) 0.348 
 
76.8 (15.0) <0.001 
Hypertension 2436 (25.3%) 1204 (25.3%) 0.988 
 
971 (22.2%) <0.001 
Serum creatinine, μmol/L 77.2 (19.7) 77.3 (19.6) 0.778 
 
75.4 ( 17.8) <0.001 
eGFR, mL/minute/1.73 m
2
 95.5 (16.4) 95.6 (16.5) 0.815 
 
97.1 (16.2) <0.001 
Reduced eGFR (n, %) 194 (2.0%) 100 (2.1%) 0.522 
 
47 (1.1%) <0.001 
Fasting blood glucose, mmol/L 4.8 (1.5) 4.8 (1.4) 0.979 
 
─ 
Total cholesterol, mmol/L 4.5 (1.3) 4.5 (1.3) 0.125 
 
─ 
Triglycerides, mmol/L 1.9 (1.5) 1.8 (1.5) 0.254 
 
─ 
HDL-cholesterol, mmol/L 1.0 (0.7) 1.0 (0.7) 0.395 
 
─ 
LDL-cholesterol, mmol/L 1.8 (1.4) 1.8 (1.4) 0.979   ─ 
Abbreviation: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low 
density lipoprotein; SD, Standard deviation. 
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a Around 2/3 of the 2012 study population were randomly selected as the training dataset and the remaining as the internal testing dataset. 
b P values refer to comparisons between subjects training dataset and internal testing dataset, using Student’s t test or Pearson’s χ2 test. 
c P values refer to comparisons between subjects training dataset and external testing dataset, using Student’s t test or Pearson’s χ2 test. 
d
 BMI = Weight (kg)/height (m)
2
. 
e
 Overweight was defined as BMI between 23−24.9 kg/m2 and obesity was defined as BMI≥25 kg/m2 in this Asian population. 
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Table 3.  Cross-Sectional Analysis of the Association between Non-invasive Variables and 
Reduced eGFR using Stepwise Logistic Regression in the Training Dataset 
    
     
Risk factors β-Coefficient OR 95% CI P value Score 
Age group, years 
     
 
≤ 40 − 1 − − − 
 
41 − 50 1.12 3.05 1.16 − 8.04 0.024 11 
 
51 − 60 2.27 9.64 3.94 − 23.58 0.000 23 
 
61 − 70 3.64 38.22 16.19 − 90.19 0.000 36 
 
71 + 4.76 117.06 51.02 − 268.60 <0.001 48 
BMI status
 a
 
     
 
Normal − 1 
 
− 
 
 
Overweight 0.43 1.55 1.09 − 2.19 0.014 4 
 
Obesity 0.47 1.60 1.10 − 2.34 0.014 5 
Gender 
     
 
Male − 1 − − − 
  Female 0.46 1.58 1.17 − 2.14 0.003 5 
Abbreviation: BMI, body mass index; OR, odds ratio; CI, confidence interval. 
a
 Overweight was defined as BMI between 23−24.9 kg/m2 and obesity was defined as 
BMI≥25 kg/m2 in this Asian population. 
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Table 4. Discrimination and Calibration of the Final Model in the Training, Internal and 
External testing dataset, respectively 
 Model discrimination  Model calibration 
 AUC 95%CI 
 Hosmer-Lemeshow test 
(P value) 
Training dataset (n = 9,621) 0.887  0.865 - 0.909  0.955 
Internal testing dataset (n = 4,753) 0.894 0.861 - 0.926  0.798 
External testing dataset (n = 4,371) 0.880 0.829 - 0.931  0.397 
Abbreviation: AUC, Area under receiver operating characteristic curve; CI, confidence 
interval. 
 
